Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-cigarettes vs. Varenicline for Smoking Cessation
NCT03630614Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2018
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nicotine in smoking cessation (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Continuous smoking abstinence rate at 12 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
nicotine
03
Conditions
smoking cessation
Beyond the preview
Go deeper on NCT03630614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630614.